MICS IOL modification does not affect PCO

Article

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount.

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount, according to recently produced data.

A research team led by Dr Birgit Weingessel, Department of Ophthalmology, Hietzing Hospital, Vienna, Austria, studied 80 eyes of 40 patients with age-related cataract.

Each participant received a 1-piece MICS IOL in one eye and a 3-piece MICS IOL in the other. After one year of follow-up patients were assessed using a slit-lamp. High-resolution images were taken to determine PCO amount and visual acuity was measured accordingly.

Mean regeneratory PCO score and the neodymium-yttrium-aluminium-garnet laser capsulotomy rate were significantly low for both IOLs. But capsular folds occurred more often in the eyes that were administered the 3-piece IOL.

The abstract can be found in the January edition of the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.